DUBLIN–(BUSINESS WIRE)–The “Lupus Nephritis – Global Clinical Trials Review, 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.
The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
The analyst Clinical Trial Reports are generated using the analyst’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create effective counter strategies to gain a competitive advantage.
Latest Clinical Trials News on Lupus Nephritis
- Oct 28, 2025: Positive Phase III Results for Roche’s Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome
- Oct 17, 2025: CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
- Oct 15, 2025: Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and ASN Kidney Week 2025
- Oct 07, 2025: Adicet Bio Announces Positive Preliminary Data From ADI-001 Phase 1 Study in Patients With Lupus Nephritis (LN) and SLE
- Aug 08, 2025: Palleon doses first subject in Phase II trial for glomerulonephritis treatment
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials, which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Key Topics Covered:
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials
- Prominent Drugs
- Clinical Trial Profile Snapshots
- Appendix
Companies Featured
- Novartis AG
- Aurinia Pharmaceuticals Inc
- Roche Holding AG
- AstraZeneca Plc
- Bristol-Myers Squibb Co
- ICON Plc
- IQVIA Holdings Inc
- Labcorp Holdings Inc
- Otsuka Holdings Co Ltd
- Parexel International Corp
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/4kpa5s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900